Results 71 to 80 of about 13,526 (188)
, 2019 Leticia Orsatti, Josep Fortea, Manuel Quaresma Boehringer Ingelheim International GmbH, Ingelheim, GermanyWe read with interest the study by Abe et al on the clinical utility of nintedanib in patients with severe idiopathic pulmonary fibrosis (IPF).
Fortea J, Quaresma M, Orsatti L
core
Medicinal Research Reviews, Volume 46, Issue 6, Page 1897-1921, November 2026.ABSTRACT Chitinase‐3‐like‐1 (CHI3L1, also known as YKL‐40) has been recognized as a biomarker of inflammation and tissue remodeling and has now emerged as a pseudoenzymatic immune checkpoint. Recent structural, immunological, and translational studies redefine it as an active regulator of immune suppression rather than a passive disease marker. Despite
Kirti Upmanyu +2 more
wiley +1 more source
Clinical development of nintedanib for advanced non-small-cell lung cancer
, 2015 Masayuki Takeda,1 Isamu Okamoto,2 Kazuhiko Nakagawa1 1Department of Medical Oncology, Kinki University Faculty of Medicine, Osaka, 2Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan ...
Okamoto I, Takeda M, Nakagawa K
core
Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 5, November 2026.ABSTRACT Background Proton pump inhibitors (PPIs) raise stomach pH, leading to reduced bioavailability of many tyrosine kinase inhibitors (TKIs), thereby affecting treatment outcomes. To what extent this interaction occurs in clinical practice remains underexplored.
Grietje van Elp +5 more
wiley +1 more source
Nintedanib in NSCLC: Evidence to date and place in therapy [PDF]
, 2016 The treatment of advanced non-small cell lung cancer (NSCLC) is currently driven by the detection of targetable oncogenic drivers, i.e. epidermal growth factor receptor, echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase, etc ...
RIZZO, Sergio +19 more
core +3 more sources
Nintedanib in the treatment of idiopathic pulmonary fibrosis
Therapeutic Advances in Respiratory Disease, 2015 Idiopathic pulmonary fibrosis (IPF) is a progressive and ultimately fatal lung disease that occurs in older adults. The clinical course of IPF is variable and hard to predict in an individual patient.
Mariano E. Mazzei +2 more
doaj +1 more source
Frontiers in Molecular Biosciences, 2020 BackgroundPirfenidone and nintedanib are the sole pharmacological therapies currently approved for idiopathic pulmonary fibrosis (IPF). Limited comparison data is available in literature, despite they are both prescribed for mild-to-moderate disease ...
Paolo Cameli +8 more
doaj +1 more source
Unraveling the epigenetic code in cancer cell–tumor microenvironment crosstalk
Molecular Oncology, Volume 20, Issue 10, Page 2510-2532, October 2026.Epigenetic regulation is a key driver of cancer development and progression. Diverse epigenetic alterations in cancer cells and components of the tumor microenvironment (TME) orchestrate their communication through multiple mechanisms. We discuss how the epigenetic code coordinates bidirectional cancer cell–TME crosstalk to promote cancer progression ...
Ji Hoon Park, Mi‐Young Kim
wiley +1 more source
Clinical Nutrition Open ScienceSummary: Background and Aims: Nintedanib is currently a therapeutic option for idiopathic pulmonary fibrosis (IPF). Weight loss is a common complication of IPF and a side effect of nintedanib, inducing loss of skeletal muscle mass and musculoskeletal ...
Hiromi Tomioka, Takashi Fujikawa
doaj +1 more source
IFN‐γ‐Associated Signaling Networks in Interstitial Lung Disease Associated With Sjögren's Disease
Immunity, Inflammation and Disease, Volume 14, Issue 10, October 2026.ABSTRACT Background Sjögren's disease (SD) is a chronic systemic autoimmune disorder that can affect multiple organ systems. Interstitial lung disease (ILD) is a clinically significant pulmonary manifestation of SD and is associated with impaired quality of life and increased mortality.
Qianqian Chen +5 more
wiley +1 more source